ClinicalTrials.gg
CompletedNCT00158093Updated Sep 12, 2005

A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo

A Phase 1 interventional study of Nebivolol and Atenolol in Hypertension, sponsored by Mylan Bertek Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2005-09-12.

Sponsored by Mylan Bertek Pharmaceuticals (part of Viatris Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies testing nebivolol in Hypertension — none open to participants now, 1 under way, none of them phase 3. Nebivolol · Hypertension.

Enrollment
17th of 58
260 · median 70
Started
2003
the only one that year
Phase 1
2 of 58
none open now
Registered
4th of 58
by date
Lead sponsor
9 of 58
Mylan Bertek Pharmaceuticals

Among the 58 studies testing nebivolol in Hypertension, this one is the 17th largest by enrollment, is the only one that started in 2003, is one of 2 in phase 1, and was the 4th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 58 studies testing nebivolol in Hypertension is open now. The open studies under Hypertension, anywhere →

About nebivolol

Nebivolol: first FDA approval 2007 (BYSTOLIC). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 58 studies testing nebivolol in Hypertension as a file.
02

Study summary

Nebivolol is one of a class of drugs known as beta-blockers. These drugs are useful in the treatment of high blood pressure, angina, abnormal heart rhythms and following a heart attack. The purpose of this study is to explore the potential of nebivolol to cause a certain type of abnormal heart rhythm, known as QTc prolongation. The potential of nebivolol to cause this adverse event will be compared to three other drugs: atenolol, a beta-blocker approved by the FDA; Avelox (moxifloxacin), an anti-biotic approved for use by the FDA which is known to cause QTc prolongation; and placebo, a drug look-alike that contains no drug. The working hypothesis was that 20 or 40 mg of nebivolol would not prolong corrected QT intervals measured during peak nebivolol concentrations (i.e., 2 hours after dosing) on Day 7.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and nonpregnant, nonlactating women were 18 years or older.
  • Women declaring or surgical sterility.
  • Women of who had a negative serum HCG within 2 weeks of dosing.
  • Male subjects weighed at least 60 kg (132 lb), and female subjects weighed at least 48 kg (106 lb). All volunteers weighed within 15% of their ideal body weight (IBW).

Exclusion criteria

Exclusion Criteria:

  • Institutionalized
  • Reported or was known to have done the following:

    • Used any tobacco product.
    • Ingested any alcoholic, caffeine or xanthine containing food or beverage within the 48 hours prior to the initial dose of study medication
    • Consumed grapefruit or grapefruit containing products within 7 days prior to the initial dose of study medication.
    • Ingested any vitamins or herbal products within the 48 hours prior to the initial dose of study medication.
    • Recently changed dietary or exercise habits significantly
  • Used any medication (including over-the-counter [OTC]) within the 14 days prior to the initial dose of study medication.
  • Used any medication known to alter hepatic enzyme activity within 28 days prior to the initial dose of study medication.
  • Received an drug within 30 days prior to the initial dose of study medication.
  • History of any significant cardiovascular, hepatic, renal, pulmonary, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease.
  • History of drug and/or alcohol abuse within 1 year prior to the study.
  • Acute illness at the time of either the pre study medical evaluation or dosing.
  • Any laboratory results deemed by the physician.
  • Abnormal and clinically relevant tracing.
  • Donated or lost a significant volume of blood or plasma (>450 mL) within 28 days prior to the initial dose of study medication.
  • Allergic or hypersensitive to nebivolol, atenolol, or other β blocking drugs or to moxifloxacin or other quinolone antibiotics.
  • History of seizures or cerebrovascular disease.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
260 participants

Interventions

06

What researchers measure

Primary outcomes

  1. The primary study endpoint was the change in the average QTc intervals from Day 0 to 2 hours after dosing on Day 7.

Secondary outcomes

  1. The secondary endpoints were the change in average QTc intervals from Day 0 to all other evaluation times and the change in other ECG intervals (PR, RR, QRS, QT) and HR from Day 0 to all other evaluation times.

07

Study locations

1 site
  • SFBC International, Inc.
    Miami, Florida 33181, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2003 and a completion of Jul 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2005
First posted
Sep 12, 2005
Start
Jun 2003
Completion
Jul 2003
Last update
Sep 12, 2005
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Sep 12, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00158093
First posted
Sep 12, 2005
Start date
Jun 2003
Completion
Jul 2003
Last update
Sep 12, 2005

Study contacts

Lawrence A Galitz, MD
principal investigator · SFBC International
Will A Sullivan, BS
study director · Mylan Bertek Pharmaceuticals Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nebivolol · Atenolol · Moxifloxacin

Start the discussion